WO2010107251A2 - 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 - Google Patents

파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2010107251A2
WO2010107251A2 PCT/KR2010/001666 KR2010001666W WO2010107251A2 WO 2010107251 A2 WO2010107251 A2 WO 2010107251A2 KR 2010001666 W KR2010001666 W KR 2010001666W WO 2010107251 A2 WO2010107251 A2 WO 2010107251A2
Authority
WO
WIPO (PCT)
Prior art keywords
pachastrissamine
prophylaxis
treatment
skin conditions
hyperproliferative skin
Prior art date
Application number
PCT/KR2010/001666
Other languages
English (en)
French (fr)
Other versions
WO2010107251A3 (ko
Inventor
신동헌
김태윤
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Publication of WO2010107251A2 publication Critical patent/WO2010107251A2/ko
Publication of WO2010107251A3 publication Critical patent/WO2010107251A3/ko
Priority to US13/236,080 priority Critical patent/US8609718B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 피토스핑고신(phytosphingosine)의 신규한 용도에 관한 것으로서 보다 상세하게는 피토스핑고신 유도체 중 하나인 파카스트리사민(pachastrissamine)을 약학적으로 허용 가능한 유효성분을 포함하는 과증식성 피부질환의 예방 및 치료용 조성물, 과증식성 피부질환 예방 및 치료제 제조를 위한 파카스트리사민 또는 이의 약학적으로 허용 가능한 염의 용도 및 파카스트리사민 또는 이의 약학적으로 허용 가능한 염을 이를 필요로 하는 개체에 유효량으로 투여하는 것을 특징으로 하는 과증식성 피부질환 치료 방법에 관한 것이다. 특히 피부각질세포의 과발현이 원인인 건선(psoriasis) 혹은 피부암 중 가장 악성 질환으로 여겨지는 악성흑색종(malingant melanoma)의 예방 및 치료에 관한 것이다. 본 발명의 파카스트리사민은 Fox03a 단백질의 발현 증가 및 분해 억제를 통한 이상증식세포의 apoptosis 유도와 세포 주기(cell cycle) 억제를 통한 세포 증식억제에 의한 질환의 예방 또는 치료 효과를 갖는다. 따라서 본 발명의 조성물, 용도 및 방법은 피부암 또는 건선 등 각종 과증식성피부질환의 예방 또는 치료의 목적으로 사용할 수 있다.
PCT/KR2010/001666 2009-03-18 2010-03-18 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물 WO2010107251A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/236,080 US8609718B2 (en) 2009-03-18 2011-09-19 Pharmaceutical composition used in treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0023190 2009-03-18
KR1020090023190A KR101201956B1 (ko) 2009-03-18 2009-03-18 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/236,080 Continuation US8609718B2 (en) 2009-03-18 2011-09-19 Pharmaceutical composition used in treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient

Publications (2)

Publication Number Publication Date
WO2010107251A2 true WO2010107251A2 (ko) 2010-09-23
WO2010107251A3 WO2010107251A3 (ko) 2011-01-06

Family

ID=42740128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001666 WO2010107251A2 (ko) 2009-03-18 2010-03-18 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물

Country Status (3)

Country Link
US (1) US8609718B2 (ko)
KR (1) KR101201956B1 (ko)
WO (1) WO2010107251A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304549A (zh) * 2013-07-04 2013-09-18 郑州大学 Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101342851B1 (ko) 2011-12-07 2013-12-17 가톨릭대학교 산학협력단 신규한 피토스핑고신 유도체 및 이를 포함하는 염증성 피부질환, 자가면역질환 및 피부과다각화증질환 예방 및 치료용 조성물
KR101288776B1 (ko) * 2011-12-07 2013-07-22 가톨릭대학교 산학협력단 신규한 피토스핑고신 유도체 및 이를 포함하는 염증성 피부질환과 피부과다각화증질환 예방 및 개선용 화장료 조성물
HUE051096T2 (hu) 2012-04-26 2021-03-01 Massachusetts Gen Hospital Ágensek és módszerek a sebészeti keratózis kezelésére és megelõzésére
KR102017562B1 (ko) * 2013-03-13 2019-09-03 (주)아모레퍼시픽 미백 효능 물질의 스크리닝 방법
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL CANALS ET AL.: 'Synthesis and biological properties ofPachastrissamine (jaspine B) and diastereoisomeric jaspines.' BIOORGANIC & MEDICINAL CHEMISTRY. vol. 17, no. 1, 18 November 2008, pages 235 - 241 *
KURODA I ET AL.: 'Pachastrissamine, a cytotoxic anhydrophytosphingosine from a marine sponge, Pachastrissa sp.' J NAT PROD. vol. 65, no. 10, October 2002, pages 1505 - 1506 *
LIU J ET AL.: 'Stereoselective synthesis ofjaspine B from D-xylose.' CARBOHYDR RES. vol. 341, no. 16, 27 November 2006, pages 2653 - 2657 *
PRASAD KR ET AL.: 'Stereoselective synthesis of cytotoxic anhydrophytosphingosine pachastrissamine [jaspine B].' J ORG CHEM. vol. 72, no. 16, 11 July 2007, pages 6312 - 6315 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304549A (zh) * 2013-07-04 2013-09-18 郑州大学 Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用
CN103304549B (zh) * 2013-07-04 2015-09-02 郑州大学 Jaspine B、3-epi Jaspine B三氮唑类衍生物、其制备方法及其应用

Also Published As

Publication number Publication date
US20120071424A1 (en) 2012-03-22
WO2010107251A3 (ko) 2011-01-06
KR101201956B1 (ko) 2012-11-19
US8609718B2 (en) 2013-12-17
KR20100104634A (ko) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2010107251A2 (ko) 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑생종의 예방 또는 치료용 약학적 조성물
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
NZ594184A (en) Skin treatment
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2012135812A3 (en) Treatment for dermatological pathologies
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
RU2014129514A (ru) [1,2,4]триазолопиридины и их применение в качестве ингибиторов фосфодиэстеразы
MX2013003523A (es) Composicion farmaceutica de dosis baja.
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECCHYMOSIS
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
RU2016135793A (ru) Композиции и способы ингибирования синтеза триглицеридов с помощью синергетической комбинации ботанических составов
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
RU2012114097A (ru) Терапевтический агент против хронической боли

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10753701

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10753701

Country of ref document: EP

Kind code of ref document: A2